@phdthesis{Schmitt2006, author = {Schmitt, Stefanie}, title = {Biomechanisch begr{\"u}ndeter Rehabilitationsansatz bei verschiedenen Krankheitsbildern des Handgelenks in der orthop{\"a}dischen Praxis : eine prospektive Studie}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-20460}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2006}, abstract = {Handgelenkserkrankungen haben sowohl in Amerika wie auch in Europa mit steigenden Fallzahlen einen durch den Ausfall der Arbeitskraft nicht unerheblichen Einfluß auf die Volkswirtschaft. St{\"a}ndige Wiederholungen in hoher Frequenz werden f{\"u}r die RSI urs{\"a}chlich verantwortlich gemacht. Basierend auf der Annahme, dass Vibrationen und Beschleunigungskr{\"a}ften mittels D{\"a}mpfk{\"o}rpern beeinflusst werden k{\"o}nnen, wurde die Coopercare Lastrap-Bandage entwickelt. Obwohl die Behandlung mit Handgelenksorthesen eine allgemein g{\"a}ngige Form der Behandlung von verschiedenen Handgelenkserkrankungen darstellt, gibt es hierzu nur sehr wenige klinische Daten {\"u}ber den Stellenwert dieser Verfahren. Daher wurde in einer prospektiven randomisierten L{\"a}ngsschnitt-Studie der Stellenwert einer Bandagenbehandlung mit biomechanisch begr{\"u}ndetem Ansatz im Vergleich zur konventionellen Bandagentherapie an 34 Patienten mit unterschiedlichen Erkrankungen des Handgelenks getestet. Unserer Studie zufolge sind entsprechend dem biomechanischen Ansatz die unter 40-j{\"a}hrigen m{\"a}nnlichen Patienten mit seit kurzem bestehender Tendovaginitis die Zielgruppe, die am Besten von einer Bandagentherapie mit der Lastrap®-Bandage profitieren. Bei unter 40-j{\"a}hrigen m{\"a}nnlichen Patienten mit Distorsion des Handgelenks ist die Manu-Hit®-Bandage zu bevorzugen. Durch die deutliche Schmerzreduktion k{\"o}nnen hier Handgelenksorthesen unter anderem den Gebrauch von NSAR verringern und damit die Arzneimittelausgaben senken.}, language = {de} } @phdthesis{JakobRodamer2014, author = {Jakob-Rodamer, Verena}, title = {Development and validation of LC-MS/MS methods to determine PK/PD parameters of anti-infectives}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-109215}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2014}, abstract = {In the present thesis the development and validation of bioanalytical LC-MS/MS methods for the quantification of erythromycin A, erythromycin ethylsuccinate, roxithromycin, clarithromycin, 14 hydroxy clarithromycin, flucloxacillin, piperacillin and moxifloxacin in human plasma and human urine (piperacillin) is introduced. All methods were applied to analyze human plasma and urine samples from clinical trials and therefore, have been validated according to international guidelines. The methods were reliable in these studies and fulfilled all regulatory requirements known at the time of the study conduct. Moreover, the validation data of the macrolides were compared on three different mass spectrometers (API III Plus, API 3000™, API 5000™). The new innovations in the ion source (horizontal versus vertical electrospray), the ionpath (skimmer, QJet) and the diameter of the orifice resulted in better sensitivity and a larger linearity range for the majority of the analytes. Sensitivity was improved up to a factor of 12 (for clarithromycin) between API III Plus to API 3000™ and up to a factor of 8 (for erythromycin and roxithromycin) between API 3000™ and API 5000™, keeping the accuracy and precision data at about the same level. The high sensitivity was a benefit for example for the flucloxacillin study, because concentrations from all subject samples were detectable up to approximately eight half-lives, i.e. no concentrations needed to be reported below the quantification limit. Also the linearity range were extended from two orders of magnitude to up to four orders of magnitude, which increases the likelihood to allow to analyze all samples from a pharmacokinetic study in the same run. This is especially useful if a large concentration range needs to be analysed, for example, if the method shall be applied in an ascending dose study. Then, all low concentrations from the beginning of the study can be determined, as well as all high concentrations, without the need to dilute and analyse single samples repeatedly. The pharmacokinetic data were compared to previously reported literature data and correlated graphically with MIC values of popular microorganisms which might be a starting point for further PK/PD investigations. The PK/PD theory is a very helpful tool for prediction of the efficacy of given drugs against certain micro-organisms. Depending on the pharmacodynamic processes, e. g. the mode of action, three classes of drugs have been identified. In the same way this applies to adverse effects, which need to be minimised by reducing plasma concentrations. These coherences are not well-investigated, yet, and are not discussed further in this thesis. Still, a lot of research has to be done in this interdisciplinary field to minimise uncertainty in single values, like an AUC/MIC. These include: Improve accuracy and precision of bioanalytical methods determining total and free concentration data in biological matrices for calculation of AUC and Cmax These parameters are related to the MIC in pharmacodynamic considerations. Since the determination of the MIC often underlies significant variations and also differences between microbiological laboratories, the determination of concentrations of anti-infectives is particular important, being achievable by scientific exact techniques. Finally, from the volume of distribution of antibiotics can be used to derive information about intracellular concentrations and effectivity of antiinfectives.}, subject = {Antimikrobieller Wirkstoff}, language = {en} } @article{JessbergerHoeggerGenestetal.2017, author = {Jessberger, Steffen and H{\"o}gger, Petra and Genest, Franca and Salter, Donald M. and Seefried, Lothar}, title = {Cellular pharmacodynamic effects of Pycnogenol\(^{®}\) in patients with severe osteoarthritis: a randomized controlled pilot study}, series = {BMC Complementary and Alternative Medicine}, volume = {17}, journal = {BMC Complementary and Alternative Medicine}, number = {537}, doi = {10.1186/s12906-017-2044-1}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-159532}, year = {2017}, abstract = {Background: The standardized maritime pine bark extract (Pycnogenol\(^{®}\)) has previously shown symptom alleviating effects in patients suffering from moderate forms of knee osteoarthritis (OA). The cellular mechanisms for this positive impact are so far unknown. The purpose of the present randomized pilot controlled study was to span the knowledge gap between the reported clinical effects of Pycnogenol\(^{®}\) and its in vivo mechanism of action in OA patients. Methods: Thirty three patients with severe OA scheduled for a knee arthroplasty either received 100 mg of Pycnogenol\(^{®}\) twice daily or no treatment (control group) three weeks before surgery. Cartilage, synovial fluid and serum samples were collected during surgical intervention. Relative gene expression of cartilage homeostasis markers were analyzed in the patients' chondrocytes. Inflammatory and cartilage metabolism mediators were investigated in serum and synovial fluid samples. Results: The oral intake of Pycnogenol\(^{®}\) downregulated the gene expression of various cartilage degradation markers in the patients' chondrocytes, the decrease of MMP3, MMP13 and the pro-inflammatory cytokine IL1B were statistically significant (p ≤ 0.05). Additionally, protein concentrations of ADAMTS-5 in serum were reduced significantly (p ≤ 0.05) after three weeks intake of the pine bark extract. Conclusions: This is the first report about positive cellular effects of a dietary supplement on key catabolic and inflammatory markers in patients with severe OA. The results provide a rational basis for understanding previously reported clinical effects of Pycnogenol\(^{®}\) on symptom scores of patients suffering from OA.}, language = {en} } @article{GenestRakPetryketal.2020, author = {Genest, Franca and Rak, Dominik and Petryk, Anna and Seefried, Lothar}, title = {Physical Function and Health-Related Quality of Life in Adults Treated With Asfotase Alfa for Pediatric-Onset Hypophosphatasia}, series = {JBMR Plus}, volume = {4}, journal = {JBMR Plus}, number = {9}, doi = {10.1002/jbm4.10395}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-218410}, year = {2020}, abstract = {Hypophosphatasia (HPP) is a rare, inherited, metabolic disease characterized by tissue-nonspecific alkaline phosphatase deficiency resulting in musculoskeletal and systemic clinical manifestations. This observational study evaluated the effectiveness of enzyme replacement therapy with asfotase alfa on physical function and health-related quality of life (HRQoL) among adults with pediatric-onset HPP who received asfotase alfa for 12 months at a single center (ClinicalTrial.gov no.: NCT03418389). Primary outcomes evaluated physical function with the 6-minute walk test (6MWT), timed up-and-go (TUG) test, Short Physical Performance Battery (SPPB), and handheld dynamometry (HHD). Secondary outcome measures included the Lower Extremity Functional Scale (LEFS), pain prevalence/intensity, and pain medication use; HRQoL was evaluated using the 36-Item Short-Form Health Survey version 2 (SF-36v2). Safety data were collected throughout the study. All 14 patients (11 women) had compound heterozygous ALPL gene mutations and ≥1 HPP bone manifestation, including history of ≥1 fracture. Mean (min, max) age was 51 (19 to 78) years. From baseline to 12 months of treatment, median 6MWT distance increased from 267 m to 320 m (n = 13; p = 0.023); median TUG test time improved from 14.4 s to 11.3 s (n = 9; p = 0.008). Specific components of the SPPB also improved significantly: median 4-m gait speed increased from 0.8 m/s to 1.1 m/s (n = 10; p = 0.007) and median repeated chair-rise time improved from 22 s to 13 s (n = 9; p = 0.008). LEFS score improved from 24 points to 53 points (n = 10; p = 0.002). Improvements in HHD were not clinically significant. SF-36v2 Physical Component Score (PCS) improved after 12 months of treatment (n = 9; p = 0.010). Pain level did not change significantly from baseline to 12 months of treatment. There were significant improvements on chair-rise time and SF-36v2 PCS by 3 months, and on TUG test time after 6 months. No new safety signals were identified. These results show the real-world effectiveness of asfotase alfa in improving physical functioning and HRQoL in adults with pediatric-onset HPP. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.}, language = {en} } @article{KasparFetteHankeetal.2021, author = {Kaspar, Mathias and Fette, Georg and Hanke, Monika and Ertl, Maximilian and Puppe, Frank and St{\"o}rk, Stefan}, title = {Automated provision of clinical routine data for a complex clinical follow-up study: A data warehouse solution}, series = {Health Informatics Journal}, volume = {28}, journal = {Health Informatics Journal}, number = {1}, doi = {10.1177/14604582211058081}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-260828}, year = {2021}, abstract = {A deep integration of routine care and research remains challenging in many respects. We aimed to show the feasibility of an automated transformation and transfer process feeding deeply structured data with a high level of granularity collected for a clinical prospective cohort study from our hospital information system to the study's electronic data capture system, while accounting for study-specific data and visits. We developed a system integrating all necessary software and organizational processes then used in the study. The process and key system components are described together with descriptive statistics to show its feasibility in general and to identify individual challenges in particular. Data of 2051 patients enrolled between 2014 and 2020 was transferred. We were able to automate the transfer of approximately 11 million individual data values, representing 95\% of all entered study data. These were recorded in n = 314 variables (28\% of all variables), with some variables being used multiple times for follow-up visits. Our validation approach allowed for constant good data quality over the course of the study. In conclusion, the automated transfer of multi-dimensional routine medical data from HIS to study databases using specific study data and visit structures is complex, yet viable.}, language = {en} } @phdthesis{Daub2023, author = {Daub, Jonas}, title = {Der Einfluss von Alter und {\"A}ngstlichkeit auf die Furchtgeneralisierung und die Aufmerksamkeitslenkung bei gesunden Kindern und Jugendlichen}, doi = {10.25972/OPUS-30010}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-300100}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2023}, abstract = {Mittels einer klinischen Studie wurden die Furchtgeneralisierung und Aufmerksamkeitslenkung von 44 gesunden Kindern und Jugendlichen im Alter von 9-17 Jahren untersucht. Eine {\"U}bergeneralisierung konditionierter Furcht sowie ver{\"a}nderte Aufmerksamkeitsprozesse werden in zahlreichen Arbeiten mit der Entstehung und Aufrechterhaltung von Angsterkrankungen in Verbindung gebracht. Der Hauptteil der Forschung beschr{\"a}nkte sich bislang auf die Untersuchung von erwachsenen Probanden. Da Angsterkrankungen jedoch h{\"a}ufig bereits im Kindes- und Jugendalter entstehen und sich in der Erforschung psychiatrischer Erkrankungen zunehmend eine dimensionale Betrachtungsweise durchsetzt, bestand das Ziel der Studie darin, etwaige Alterseffekte und den Einfluss der {\"A}ngstlichkeit auf die genannten Ph{\"a}nomene bei gesunden Probanden zu untersuchen. Dar{\"u}ber hinaus wurde ein potentiell pr{\"a}ventiver Ansatz erforscht. Im Ergebnis zeigten sich in den Gruppenvergleichen keine relevanten Differenzen. Interessanterweise deutete sich in der Gruppe der {\"a}lteren Probanden entgegen der Erwartung eine verst{\"a}rkte Furchtgeneralisierung an, die wom{\"o}glich mit einer ver{\"a}nderten Beziehung zu Furcht und Risiko in der Adoleszenz zusammenh{\"a}ngt. Aus den Befunden ergibt sich die Notwendigkeit weiterer, prospektiver Arbeiten, um unser Verst{\"a}ndnis der {\"A}tiologie von Angsterkrankungen zu verbessern. Weiterhin ist noch offen, inwiefern es sich bei der {\"U}bergeneralisierung und einer ver{\"a}nderten Aufmerksamkeitslenkung um Risikofaktoren f{\"u}r die Entwicklung von Angsterkrankungen oder vielmehr um Epiph{\"a}nomene handelt, die erst mit Ausbruch der Erkrankung auftreten. Der Einsatz von Methoden der virtuellen Realit{\"a}t erscheint besonders geeignet, diese Prozesse zuk{\"u}nftig noch besser zu erforschen.}, subject = {Angst}, language = {de} }